{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-028075","form_type":"8-K","ticker":"AKTX","cik":"0001541157","company_name":"Akari Therapeutics Plc","filed_at":"2025-12-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.693006+00:00","generated_at":"2026-05-16T12:54:55.925375+00:00","sec_items":["1.01","3.02","1.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Akari raises ~$5M in equity; exchanges $4M notes for warrants","bullets":["Gross proceeds ~$5M from 10,043,774 ADSs at $0.3883/unit plus pre-funded warrants to insiders for $1M+.","Non-cash reduction of ~$4M in 2026 Notes via exchange for pre-funded warrants and Note Exchange Warrants.","Warrants exercisable after shareholder approval; Series G exercise price $0.3883, 5-year term.","Ladenburg Thalmann acts as placement agent; 8.0% fee, 0.5% mgmt fee, and 504,300 placement agent warrants.","Net proceeds for R&D and working capital; offering closed Dec. 17, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-028075","json":"https://secwatch.observer/filing/0001493152-25-028075.json","markdown":"https://secwatch.observer/filing/0001493152-25-028075.md","text":"https://secwatch.observer/filing/0001493152-25-028075.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1541157/000149315225028075/0001493152-25-028075-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1541157/000149315225028075/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T12:54:55.925375+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}